TEAM	POST	TIME	RESEARCH TASK					VISIT	COLLABORATION	
			Systems biology	Genomics	Proteomics	Metabolomics	Physiomics			
KUO	ESR 1	1-36	P: PPAR target gene characterization					WAG	WAG, SGUL, ERA, BIR, IIB, KUL, OUL,	
	ESR 2	13-48	G	G: SNPs in NR REs				VUA VUA, BXL		
BIR	ESR 3	1-36			pigenetic anisms			KUO	MAX, WIE, OUL, WIE, Unilever	
	ESR 4	13-48				P: In vivo reg PPAR li		MAX		
ERA	ESR 5	1-36	D			NRs in bone pathology		VUA	KUL, KUO, BIR, UniS, IIB, SGUL,	
	ESR 6	13-48		ional gene orphism				SGUL	VUA VUA	
UniS	ESR 7	1-36	P/D: NR-cofactor interactions in stereogenesis				genesis	OUL	BIR, ERA, OUL, WIE, Unilever	
VUA	ESR 8	1-36	P/G/D: Construction of unified models of NR actions					KUO	KUO, WAG, data	
	ESR 9	13-48	P/G/D: Binary model of gene regulation					WAG	from all teams	
WAG	ESR 10	1-36	P: PPAR target genes					Unilever	KUL, KUO, OUL, Unilever, VUA, IIB	
OUL	ESR 11	13-48	P/D: NR regul			ation of CYP family		UniS	KUO, WAG, BIR, WIE, Unilever, UniS	
KUL	ESR 12	1-36	G/D: NR target genes in proliferation NR					ERA	ERA, BIR, KUO, Unilever, WAG, UniS, IIB	
Unilever	ESR 13	13-48	P: NR actions in differen			entiating skin		ERA	ERA, KUO, OUL, UniS, BIR	
ΙΙΒ	ESR 14	13-48		G/D: VDR target genes in colon cancer cells				KUL	BIR, WIE, KUL, KUO, BXL	
MAX	ESR 15	13-48				P/G/D: Transge	enic NR study	BIR	WIE, KUL, BIR, ERA	
SGUL	ESR 16	1-36	G: NR polymorphisms in cancer					KUL	IIB, KUO, WIE, BIR, KUL, BXL	
WIE	ESR 17	1-36	D: In v			vivo studies of diet/cancer		BIR	IIB, MAX, SGUL, UniS, KUL, BIR	
BXL	ESR 18	13-48				P/D: In vivo NR therapeutics		WIE	KUO, WIE, BIR, KUL	

Table 1: The distribution and scheduling of researchers and tasks. Each ESR post has an identified team for a long-tern visit and a group of other teams with whom closer collaboration will be maintained. The ESR posts have a specific project, which will unite at least two research tasks, within the context of one or more Thematic Tasks, \mathbf{P} = Thematic Area 1 (PPAR), \mathbf{G} = Thematic Area 2 (GENO), \mathbf{D} = Thematic Area 3 (DIFF)